University of Geneva, Campus Biotech
Geneva, 1202, Switzerland
Location status: Recruiting
Location contact
Lucie Bréchet, PhD
CONTACT
Lucie Bréchet, PhD
PRINCIPAL_INVESTIGATOR
Paul G Unschuld, PhD
SUB_INVESTIGATOR
NCT Number: NCT05708001
The Clinical Trial will systematically examine the feasibility of remote, caregiver-led tACS for older adults with memory deficits and evaluate whether repeated tACS leads to sustained improvement of neuronal activity and memory functions.
Interested in participating?
Request Info55 year–85 year
All sexes
Interventional
Not applicable
Geneva, 1202, Switzerland
Location status: Recruiting
Lucie Bréchet, PhD
CONTACT
Lucie Bréchet, PhD
PRINCIPAL_INVESTIGATOR
Paul G Unschuld, PhD
SUB_INVESTIGATOR
The proposed investigation will systematically examine the feasibility and efficacy of remote, caregiver-led tACS for older adults with memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access to tACS as a part of memory decline prevention and treatment for older adults.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Mild Cognitive Impairment (MCI) patients
Caregiver
Exclusion criteria
Mild Cognitive Impairment (MCI) patients
Caregiver
tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of <30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
Time frame: baseline, after 4 weeks
The primary objective is to characterize cognitive status at baseline and after 4 weeks of the home-based stimulation intervention.
Time frame: baseline, after 4 weeks,
The secondary objective is to assess with hdEEG any changes in gamma power at baseline and after 4 weeks of the home-based stimulation intervention.
Contact information is provided by the study sponsor or research team.
Lucie Bréchet
Other
Improvement of Memory in Mild Cognitive Impairment (MCI) Using Transcranial Alternating Current Stimulation (tACS) Guided by EEG and MRI: a Randomized, Sham-controlled, Parallel-arm, Double-blind Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07169630
Alzheimer s Disease, Cognition Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT07735910
Anxiety Disorders, Behavior
Shenyang, Liaoning, China
View Trial DetailsNCT07731334
Brain Diseases, Central Nervous System Diseases
Florence, FI, Italy
View Trial DetailsNCT06072963
Alzheimer Disease, Brain Diseases
Ramat Gan, Israel
View Trial Details